ClinicalTrials.gg
CompletedNCT01012258CHANCEUpdated Jul 9, 2015Results posted

Cetuximab With Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese Subjects

A Phase 3 interventional study of Cetuximab + concomitant boost radiotherapy in Squamous Cell Carcinoma of the Head and Neck, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 8 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-07-09.

Sponsored by Merck KGaA, Darmstadt, Germany · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
70
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 86 studies testing cetuximab in Squamous Cell Carcinoma of Head and Neck — 11 open to participants now, 19 under way, 7 of them phase 3. Cetuximab · Squamous Cell Carcinoma of Head and Neck.

Enrollment
26th of 84
70 · median 46
Started
2009
with 8 others
Phase 3
16 of 86
4 open now
Registered
29th of 86
by date
Lead sponsor
4 of 86
Merck KGaA, Darmstadt, Germany

Among the 86 studies testing cetuximab in Squamous Cell Carcinoma of Head and Neck, this one is the 26th largest by enrollment of the 84 interventional ones that give a count, is one of 9 that started in 2009, is one of 16 in phase 3, and was the 29th registered.

Squamous Cell Carcinoma of Head and Neck

2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

11 of the 86 studies testing cetuximab in Squamous Cell Carcinoma of Head and Neck are open now, in 4 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About cetuximab

Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies testing cetuximab in Squamous Cell Carcinoma of Head and Neck, or all of them as a file.
02

Study summary

Primary objective: to assess the antitumor activity and safety profile of cetuximab when given in combination with radiotherapy (RT) for the treatment of locally advanced squamous cell carcinoma of the head and neck (SCCHN) in Chinese subjects.

Secondary objective: to assess the pharmacokinetic (PK) profile and immunogenicity of cetuximab in Chinese subjects.

Further objective: to identify for cetuximab potential predictive biomarkers of response and safety.

03

Conditions studied

  • Squamous Cell Carcinoma of the Head and Neck

Keywords

  • antitumor activity
  • safety
  • cetuximab in combination with radiotherapy
  • locally advanced squamous cell head & neck carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Inpatient greater than or equal to (>=) 18 years of age
  • proven squamous cell carcinoma arising in the oropharynx, hypopharynx or larynx
  • Stage III or IV disease with an expected survival of at least 12 months
  • Medically suitable to withstand a course of concomitant boost RT
  • Presence of at least 1 bi-dimensionally identified either by computed tomography (CT) scan or magnetic resonance imaging (MRI) according to modified World Health Organization (WHO) criteria
  • Performance Status (KPS) >=80 at trial entry
  • Neutrophils >=1.5*10\^9/Liter (L), count >= 100*10\^9/L, >= 90 gram/liter (g/L)
  • Total less than or equal to (\<=) 2* (ULN); (AST) and alanine aminotransferase (ALT) \<= 3*ULN
  • Serum creatinine \<=133 micromole/liter (mcmol/L)
  • Serum calcium within normal range
  • Effective if procreative potential exists (applicable to both male and female subjects)
  • Chinese with Chinese citizenship
  • Signed written

Exclusion criteria

Exclusion Criteria:

  • Evidence of distant disease
  • Squamous cell carcinoma arising in the nasopharynx or oral cavity
  • Receipt of prior systemic chemotherapy within the last 3 years
  • Previous surgery for the tumor under study other than
  • Receipt of prior RT to the head and neck
  • Currently receiving RT as part of a postoperative regimen following primary surgical resection
  • Planned neck dissection after trial RT
  • Active infection (infection requiring IV antibiotics), including active tuberculosis, or known and declared (HIV)
  • Uncontrolled diabetes mellitus, pulmonary fibrosis, acute pulmonary disorder, interstitial pneumonia, cardiac failure or liver failure
  • Uncontrolled hypertension defined as systolic blood pressure >=180 millimeter of mercury (mmHg) and/or diastolic blood pressure >=130 mmHg under resting conditions
  • Pregnancy (absence to be confirmed by serum beta human chorionic gonadotrophin [beta-HCG] test) or breastfeeding
  • Concomitant chronic systemic immune therapy or hormonal therapy as cancer therapy
  • Other concomitant anticancer therapies
  • Documented or symptomatic brain or
  • coronary artery disease or history of myocardial infarction in the last 12 months or high risk of uncontrolled arrhythmia or uncontrolled cardiac insufficiency
  • Previous treatment with monoclonal antibody therapy, other signal transduction inhibitors or epidermal growth factor receptor (EGFR) targeting therapy
  • Evidence of previous other within the last 5 years
  • Intake of any medication within 30 days before trial entry
  • Other protocol-defined exclusion criteria may apply
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    Cetuximab

    All eligible subjects will receive cetuximab treatment only during week 1 of the treatment course and concomitant cetuximab and boost radiotherapy (RT) during week two to week seven of the treatment course

    Biological: Cetuximab + concomitant boost radiotherapy

Interventions

  • BiologicalCetuximab + concomitant boost radiotherapy

    Drug page: Cetuximab

    Cetuximab 400 milligram/square meter (mg/m\^2) intravenous (IV) infusion over 120 minutes for 1 week, subsequently followed by 250 mg/m\^2 IV infusion over 60 minutes, from week 2 to 7 along with concomitant boost radiotherapy: 72.0 Gray (Gy) total for 42 fractions in 6 weeks, initially * Once-daily fractions: 32.4 Gy in 18 fractions of 1.8 Gy for 3.6 weeks (5 fractions/week), followed by * Twice-daily fractions 39.6 Gy in 24 fractions for 2.4 weeks: morning dose 1.8 Gy/fraction for a total of 12 fractions 5 fractions/week; evening dose 1.5 Gy/fraction for a total of 12 fractions 5 fractions/week. Doses are separated by at least a 6-hour interval

    Also known as: Erbitux®

06

What researchers measure

Primary outcomes

  1. Best Overall Response (BOR)

    Best overall (objective) response was defined as the occurrence of complete response (CR) or partial response (PR) based on the investigator's assessment according to modified World Health Organization (WHO) criteria confirmed at a repeat assessment performed no less than 28 days after the criteria for response were first met. CR was defined as disappearance of all index lesions. PR was defined as a 50% or more decrease in the sum of the products of diameters (SOPD) of index lesions compared to the baseline SOPD, with no evidence of PD.

    Time frame: Baseline until the date of first documented progression or discontinuation from the study due to any cause, assessed every 3 months following the 8 weeks after the end of RT visit until the end of trial (EOT) visit

Secondary outcomes

  1. Progression-Free Survival (PFS)

    Progression-free survival was defined as the duration (in months) from first administration of trial treatment to first observation of PD (radiological or clinical, if radiological PD is not available), or death due to any cause. The PFS time of participants without observation of PD but death occurring after two or more missed consecutive tumor assessments (i.e. two-fold scheduled time interval of two consecutive tumor assessments) was censored on the date of last tumor assessment or first administration of trial treatment (whichever was later).

    Time frame: Baseline up to disease progression or withdrawal or 12 weeks after the last radiotherapy of the last participant

07

Results

Posted Aug 14, 2012

Participant flow

Participant flow — Overall Study
MilestoneCetuximab
Started66
Completed0
Not completed66
Withdrew: Death14
Withdrew: Lost to follow-up1
Withdrew: Adverse event1
Withdrew: Progressive disease (pd)18
Withdrew: Symptomatic deterioration1
Withdrew: Another anti-cancer drug received1
Withdrew: Another tumor discovered1
Withdrew: Ongoing29

Outcome measures

PrimaryBest Overall Response (BOR)

Best overall (objective) response was defined as the occurrence of complete response (CR) or partial response (PR) based on the investigator's assessment according to modified World Health Organization (WHO) criteria confirmed at a repeat assessment performed no less than 28 days after the criteria for response were first met. CR was defined as disappearance of all index lesions. PR was defined as a 50% or more decrease in the sum of the products of diameters (SOPD) of index lesions compared to the baseline SOPD, with no evidence of PD.

Time frame:
Baseline until the date of first documented progression or discontinuation from the study due to any cause, assessed every 3 months following the 8 weeks after the end of RT visit until the end of trial (EOT) visit
Reported as:
Number · percentage of participants
Best Overall Response (BOR)
percentage of participantsCetuximab
Best Overall Response (BOR)68.2 (55.6 to 79.1)
SecondaryProgression-Free Survival (PFS)

Progression-free survival was defined as the duration (in months) from first administration of trial treatment to first observation of PD (radiological or clinical, if radiological PD is not available), or death due to any cause. The PFS time of participants without observation of PD but death occurring after two or more missed consecutive tumor assessments (i.e. two-fold scheduled time interval of two consecutive tumor assessments) was censored on the date of last tumor assessment or first administration of trial treatment (whichever was later).

Time frame:
Baseline up to disease progression or withdrawal or 12 weeks after the last radiotherapy of the last participant
Reported as:
Median · months
Progression-Free Survival (PFS)
monthsCetuximab
Progression-Free Survival (PFS)9.4 (7.7 to 11.2)

Adverse events

Collected over Up to Day 60 after last trial treatment administration and before EOT. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cetuximab: Treatment Emergent Phase—5/66 (7.6%)64/66 (97%)
Cetuximab: Late Phase—14/62 (22.6%)20/62 (32.3%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventCetuximab: Treatment Emergent PhaseCetuximab: Late Phase
Lung infectionInfections and infestations1/662/62
CachexiaMetabolism and nutrition disorders1/662/62
Pharyngeal hemorrhageRespiratory, thoracic and mediastinal disorders0/662/62
Drug hypersensitivityImmune system disorders2/660/62
Iron deficiency anemiaBlood and lymphatic system disorders0/661/62
HematemesisGastrointestinal disorders0/661/62
Upper gastrointestinal hemorrhageGastrointestinal disorders0/661/62
Localized edemaGeneral disorders0/661/62
Sudden deathGeneral disorders0/661/62
PneumoniaInfections and infestations0/661/62
Most frequent other events
Showing 10 of 91
Most frequent other events
EventCetuximab: Treatment Emergent PhaseCetuximab: Late Phase
Mucosal inflammationGeneral disorders52/660/62
Weight decreasedInvestigations34/6611/62
Dermatitis acneiformSkin and subcutaneous tissue disorders21/660/62
Dry mouthGastrointestinal disorders15/661/62
PyrexiaGeneral disorders14/660/62
Oropharyngeal painRespiratory, thoracic and mediastinal disorders13/660/62
Exfoliative rashSkin and subcutaneous tissue disorders13/660/62
AcneSkin and subcutaneous tissue disorders11/660/62
White blood cell count decreasedInvestigations10/662/62
Skin hyperpigmentationSkin and subcutaneous tissue disorders10/660/62

Baseline characteristics

Age, Continuous
Age, Continuous(years)Cetuximab
Mean55.8 ± 9.5
Age, Customized
Age, Customized(participants)Cetuximab
<65 years52
>=65 years14
Sex: Female, Male
Sex: Female, Male(Participants)Cetuximab
Female7
Male59
08

Study locations

8 sites
  • Fujian Provincial Tumor Hospital
    Fuzhou, Fujian, China
  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    Beijing, China
  • Xiangya Hospital of Central South University
    Changsha, Hunan, China
  • Sun Yat-sen University Cancer Center
    Guangzhou, China
  • Zhejiang Provincial Cancer Hospital
    Hangzhou, China
  • Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine
    Shanghai, China
  • Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei, China
  • Zhongnan Hospital of Wuhan University
    Wuhan, Hubei, China
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2009, a primary completion of Sep 2010 and a completion of May 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2012, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2009
First posted
Nov 13, 2009
Start
Feb 2009
Primary completionActual
Sep 2010
CompletionActual
May 2014
Results first posted
Aug 14, 2012
Last update
Jul 9, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01012258
Responsible party
Sponsor
First posted
Nov 13, 2009
Start date
Feb 2009
Primary completion
Sep 2010
Completion
May 2014
Results posted
Aug 14, 2012
Last update
Jul 9, 2015

Study contacts

Li Gao
principal investigator · Radiotherapy Department, Cancer Institute & Hospital, Chinese Academy of Medical Science, Beijing, China
Junliang Cai
study director · Merck Serono (Beijing) Pharmaceutical R&D Co., Ltd., an Affiliate of Merck KGaA, Darmstadt, Germany
Guozhen Xu
principal investigator · Radiotherapy Department, Cancer Institute & Hospital, Chinese Academy of Medical Science, Beijing, China

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cetuximab

Start the discussion